Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Environ Toxicol ; 33(10): 1069-1077, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-30098279

RESUMEN

The present study was designed to evaluate the protective effects of hesperidin, a flavonoid on DEN initiated and Fe-NTA promoted renal carcinogenesis in Wistar rats. Renal cancer was initiated by a single i.p. injection of DEN (200 mg/kg b.wt.) and promoted with Fe-NTA (9 mg Fe/kg b.wt. i.p.) twice a week for 16 weeks. Rats were simultaneously administered with hesperidin (100 and 200 mg/kg b.wt.) for 16 consecutive weeks. The chemopreventive effect of hesperidin was assessed in terms of antioxidant activities, renal function, PGE2 level, and the expressions of COX-2 and VEGF. Hesperidin decreased the DEN and Fe-NTA induced lipid peroxidation, improved the renal function (by decreasing the levels of BUN, creatinine, and KIM-1) and restored the renal antioxidant armory (GSH, GPx, GR, SOD, and catalase). Hesperidin was also found to decrease the level of PGE2 and downregulate the expressions of COX-2 and VEGF. Histological findings further revealed the protective effects of hesperidin against DEN and Fe-NTA induced kidney damage. The result of our present findings suggest that hesperidin may be a promising modulator in preventing renal cancer possibly by virtue of its ability to alleviate oxidative stress and inhibit COX-2/PGE2 pathway.


Asunto(s)
Anticarcinógenos/uso terapéutico , Carcinoma de Células Renales/tratamiento farmacológico , Ciclooxigenasa 2/metabolismo , Dinoprostona/metabolismo , Hesperidina/uso terapéutico , Neoplasias Renales/tratamiento farmacológico , Animales , Anticarcinógenos/farmacología , Antioxidantes/metabolismo , Carcinogénesis/inducido químicamente , Carcinogénesis/efectos de los fármacos , Carcinoma de Células Renales/inducido químicamente , Carcinoma de Células Renales/metabolismo , Proliferación Celular/efectos de los fármacos , Dietilnitrosamina , Compuestos Férricos , Hesperidina/farmacología , Riñón/metabolismo , Neoplasias Renales/inducido químicamente , Neoplasias Renales/metabolismo , Peroxidación de Lípido , Masculino , Ácido Nitrilotriacético/análogos & derivados , Estrés Oxidativo , Extractos Vegetales/farmacología , Ratas Wistar
2.
Arch Biochem Biophys ; 606: 1-9, 2016 09 15.
Artículo en Inglés | MEDLINE | ID: mdl-27403965

RESUMEN

Chrysin (CH) is natural, biologically active compound, belongs to flavoniod family and possesses diverse pharmacological activities as anti-inflammatory, anti-oxidant and anti-cancer. It is found in many plants, honey and propolis. In the present study, we investigated the chemopreventive efficacy of CH against N-nitrosodiethylamine (DEN) initiated and Fe-NTA induced precancerous lesions and its role in regulating oxidative injury, hyperproliferation, tumor incidences, histopathological alterations, inflammation, and apoptosis in the kidneys of Wistar rats. Renal cancer was initiated by single intraperitoneal (i.p.) injection of DEN (200 mg/kg bw) and promoted by twice weekly injection of ferric nitrilotriacetate (Fe-NTA) 9 mg Fe/kg bw for 16 weeks. CH attenuated Fe-NTA enhanced renal lipid peroxidation, serum toxicity markers and restored renal anti oxidant armory significantly. CH supplementation suppressed the development of precancerous lesions via down regulation of cell proliferation marker like PCNA; inflammatory mediators like TNF-α, IL-6, NFkB, COX-2, iNOS; tumor incidences. CH up regulated intrinsic apoptotic pathway proteins like bax, caspase-9 and caspase-3 along with down regulation of Bcl-2 triggering apoptosis. Histopathological and ultra structural alterations further confirmed biochemical and immunohistochemical results. These results provide powerful evidence for the chemopreventive efficacy of CH against chemically induced renal carcinogenesis possibly by modulation of multiple molecular pathways.


Asunto(s)
Flavonoides/química , Regulación Neoplásica de la Expresión Génica , Neoplasias Renales/prevención & control , Lesiones Precancerosas/fisiopatología , Animales , Anticarcinógenos/química , Antioxidantes/química , Apoptosis , Carcinogénesis , Proliferación Celular , Compuestos Férricos , Inflamación , Riñón/patología , Neoplasias Renales/fisiopatología , Peroxidación de Lípido , Masculino , Ácido Nitrilotriacético/análogos & derivados , Estrés Oxidativo , Lesiones Precancerosas/inducido químicamente , Ratas , Ratas Wistar , Regulación hacia Arriba
3.
Mol Cell Biochem ; 416(1-2): 169-77, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-27116616

RESUMEN

Hepatocellular carcinoma is one of the most common lethal diseases worldwide and there is no effective treatment till date. Natural products derived from the plants play an important role in chemoprevention and act as therapeutic antitumor agents. Licorice is a plant that has been used in food and medicine for the treatment of various diseases. 18ß-Glycyrrhetinic acid (18ß-GA), a pentacyclic triterpenoid obtained from the roots of licorice plant, is reported to possess various pharmacological properties such as antitumor and antiinflammatory activities. The present study was designed to elucidate the chemopreventive effect of 18ß-GA through antiinflammation, antiproliferation, and induction of apoptosis in human hepatoma cell line HepG2. 18ß-GA significantly inhibits the proliferation of HepG2 cell without affecting the normal liver cell line (Chang's). In the present study, 18ß-GA increased the formation of reactive oxygen species, nitric oxide production, and loss of mitochondrial membrane potential, suggesting the involvement of 18ß-GA in apoptosis which was also confirmed by assessing the markers involved in apoptosis like caspase-3, caspase-9, Bax:Bcl-2 ratio, and cleaved PARP. 18ß-GA also downregulated the expression of inflammatory proteins such as NF-κB, iNOS, and COX-2. Keeping these data into consideration, our results suggest that 18ß-GA may be used as a chemopreventive agent in liver cancer.


Asunto(s)
Proteínas Reguladoras de la Apoptosis/biosíntesis , Apoptosis/efectos de los fármacos , Biomarcadores de Tumor/biosíntesis , Carcinoma Hepatocelular/metabolismo , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Ácido Glicirretínico/análogos & derivados , Mediadores de Inflamación/metabolismo , Neoplasias Hepáticas/metabolismo , Proteínas de Neoplasias/biosíntesis , Carcinoma Hepatocelular/patología , Ácido Glicirretínico/farmacología , Células Hep G2 , Humanos , Neoplasias Hepáticas/patología
4.
Mol Cell Biochem ; 406(1-2): 9-20, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25994504

RESUMEN

Trichloroethylene (TCE), a nephrotoxicant is known to cause severe damage to the kidney. In this study, the nephroprotective potential of hesperidin was evaluated against TCE-induced nephrotoxicity in wistar rats. Oral administration of TCE (1000 mg/kg b.wt) for 15 days enhanced renal lipid peroxidation and reduced antioxidant enzymes armoury viz., reduced renal glutathione, glutathione peroxidase, glutathione reductase, glutathione-S-transferase, catalase and superoxide dismutase. It also enhanced the levels of blood urea nitrogen, creatinine and kidney injury molecule (KIM-1). Caspase-3 and bax expression were found to be elevated, while that of bcl-2 reduced suggesting that TCE induces apoptosis. However, pretreatment with hesperidin at a dose of 100 and 200 mg/kg b.wt for 15 days significantly decreased lipid peroxidation, increased the levels of antioxidant enzymes and reduced blood urea, creatinine and KIM-1 levels. Hesperidin also modulated the apoptotic pathways by altering the expressions of caspase-3, bax and bcl-2 to normal. Our results suggest that hesperidin can be used as a nephroprotective agent against TCE-induced nephrotoxicity.


Asunto(s)
Antioxidantes/farmacología , Apoptosis , Hesperidina/farmacología , Riñón/metabolismo , Estrés Oxidativo/efectos de los fármacos , Animales , Antioxidantes/uso terapéutico , Proteínas Reguladoras de la Apoptosis/metabolismo , Catalasa/metabolismo , Evaluación Preclínica de Medicamentos , Glutatión/metabolismo , Glutatión Peroxidasa/metabolismo , Glutatión Reductasa/metabolismo , Glutatión Transferasa/metabolismo , Hesperidina/uso terapéutico , Riñón/efectos de los fármacos , Riñón/patología , Masculino , Malondialdehído/metabolismo , Ratas Wistar , Insuficiencia Renal/inducido químicamente , Insuficiencia Renal/metabolismo , Superóxido Dismutasa/metabolismo , Tricloroetileno
5.
Exp Mol Pathol ; 99(3): 641-53, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26551080

RESUMEN

In the present study, chemopreventive efficacy of hesperidin was evaluated against ferric nitrilotriacetate (Fe-NTA) induced renal oxidative stress and carcinogenesis in wistar rats. Nephrotoxicity was induced by single intraperitoneal injection of Fe-NTA (9 mg Fe/kg b.wt). Renal cancer was initiated by the administration of N-nitrosodiethylamine (DEN 200mg/kg b.wt ip) and promoted by Fe-NTA (9 mg Fe/kg b.wt ip) twice weekly for 16 weeks. Efficacy of hesperidin against Fe-NTA-induced nephrotoxicity was assessed in terms of biochemical estimation of antioxidant enzyme activities viz. reduced renal GSH, glutathione peroxidase, glutathione reductase, glutathione-S-transferase, catalase, superoxide dismutase and renal toxicity markers (BUN, Creatinine, KIM-1). Administration of Fe-NTA significantly depleted antioxidant renal armory, enhanced renal lipid peroxidation as well as the levels of BUN, creatinine and KIM-1. However, simultaneous pretreatment of hesperidin restored their levels in a dose dependent manner. Expression of apoptotic markers caspase-3, caspase-9, bax, bcl-2 and proliferative marker PCNA along with inflammatory markers (NFκB, iNOS, TNF-α) were also analysed to assess the chemopreventive potential of hesperidin in two-stage renal carcinogenesis model. Hesperidin was found to induce caspase-3, caspase-9, bax expression and downregulate bcl-2, NFκB, iNOS, TNF-α, PCNA expression. Histopathological findings further revealed hesperidin's chemopreventive efficacy by restoring the renal morphology. Our results provide a powerful evidence suggesting hesperidin to be a potent chemopreventive agent against renal carcinogenesis possibly by virtue of its antioxidant properties and by modulation of multiple molecular pathways.


Asunto(s)
Carcinogénesis/efectos de los fármacos , Carcinoma de Células Renales/prevención & control , Hesperidina/farmacología , Neoplasias Renales/prevención & control , Estrés Oxidativo/efectos de los fármacos , Animales , Apoptosis/efectos de los fármacos , Carcinógenos/toxicidad , Carcinoma de Células Renales/inducido químicamente , Proliferación Celular/efectos de los fármacos , Modelos Animales de Enfermedad , Compuestos Férricos/toxicidad , Inmunohistoquímica , Neoplasias Renales/inducido químicamente , Masculino , Ácido Nitrilotriacético/análogos & derivados , Ácido Nitrilotriacético/toxicidad , Ratas , Ratas Wistar , Transducción de Señal/efectos de los fármacos
6.
Life Sci ; 321: 121535, 2023 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-36906255

RESUMEN

MicroRNAs are critical regulators of the plethora of genes, including FOXO "forkhead" dependent transcription factors, which are bonafide tumour suppressors. The FOXO family members modulate a hub of cellular processes like apoptosis, cell cycle arrest, differentiation, ROS detoxification, and longevity. Aberrant expression of FOXOs in human cancers has been observed due to their down-regulation by diverse microRNAs, which are predominantly involved in tumour initiation, chemo-resistance and tumour progression. Chemo-resistance is a major obstacle in cancer treatment. Over 90% of casualties in cancer patients are reportedly associated with chemo-resistance. Here, we have primarily discussed the structure, functions of FOXO and also their post-translational modifications which influence the activities of these FOXO family members. Further, we have addressed the role of microRNAs in carcinogenesis by regulating the FOXOs at post-transcriptional level. Therefore, microRNAs-FOXO axis can be exploited as a novel cancer therapy. The administration of microRNA-based cancer therapy is likely to be beneficial to curb chemo-resistance in cancers.


Asunto(s)
MicroARNs , Neoplasias , Humanos , MicroARNs/genética , MicroARNs/metabolismo , Neoplasias/tratamiento farmacológico , Neoplasias/genética , Factores de Transcripción Forkhead/genética , Factores de Transcripción Forkhead/metabolismo , Procesamiento Proteico-Postraduccional , Diferenciación Celular
7.
Life Sci ; 308: 120922, 2022 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-36058262

RESUMEN

Renal cell carcinoma (RCC) is one of the most common kidney cancers, responsible for nearly 90 % of all renal malignancies. Despite the availability of many treatment strategies, RCC still remains to be an incurable disease due to its resistivity towards conventional therapies. Nanotechnology is an emerging field of science that offers newer possibilities in therapeutics including cancer medicine, specifically by targeted delivery of anticancer drugs. Several phytochemicals are known for their anti-cancer properties and have been regarded as chemopreventive agents. However, the hydrophobic nature of many phytochemicals decreases its bioavailability and distribution, thus showing limited therapeutic effect. Application of nanotechnology to enhance chemoprevention is an effective strategy to increase the bioavailability of phytochemicals and thereby its therapeutic efficacy. The present review focuses on the utility of nanotechnology in RCC treatment and chemopreventive agents of RCC. We have also visualized the future prospects of nanomolecules in the prevention and cure of RCC.


Asunto(s)
Anticarcinógenos , Carcinoma de Células Renales , Neoplasias Renales , Anticarcinógenos/uso terapéutico , Carcinoma de Células Renales/tratamiento farmacológico , Carcinoma de Células Renales/patología , Carcinoma de Células Renales/prevención & control , Quimioprevención , Humanos , Neoplasias Renales/tratamiento farmacológico , Neoplasias Renales/patología , Neoplasias Renales/prevención & control , Fitoquímicos/uso terapéutico
8.
Pak J Pharm Sci ; 23(4): 417-22, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20884456

RESUMEN

Variations of cytochrome-P450 enzyme system (CYP2CP) are associated with impaired metabolism of warfarin. The objective of our study was to estimate the frequency of genetic and allelic variants of CYP2C9 in Punjabi population of Pakistan and their effects on warfarin dose requirement. One hundred and twenty unrelated Pakistani subjects belong to Punjab province, were randomly included from the registry of National Institute of Heart Disease Rawalpindi, Pakistan. The patients had stable international normalized ratio (INR) of 2 to 3 for last 3 months with warfarin therapy after heart valves replacement. The detection of CYP2C9 variant was done on polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Total 120 patients (73 males; 47 females) of mean age of 37 years participated in the study. Nine patients had mutant allele CYP2C9*3 (7.5%), one CYP2C9*2 (0.8%) and 110 patients exhibited wild type CYP2C9*1 (91.7%). The frequency of CYP2C9 genotype was *1/*1 (0.858) ; *1/*3 (0.117) ; 2/*20 (0.08 ) and *3/*3 (0.017) in our study population. A high dose of warfarin (42.2+9.56) mg/week is required for patients with *1/*1 genotype as compared to patients with *2/*2 (17.5+1.9) and *1/*3 (16.6+2.3) allele (p<0.001). Individuals with CYP2C9*3/3* need lowest (8.75±1.76 mg/week) daily warfarin dose. In conclusion, the genetic variations in the CYP2C9 occur in 14% of Punjabi ethnic group in Pakistan. Presence of CYP2C9*2 or *3 variants is an independent predictor of low warfarin dose requirement in our patients. CYP2C9 variants assay may be used in high risk groups for appropriate dose adjustment to avoid complications on long term basis.


Asunto(s)
Anticoagulantes/administración & dosificación , Anticoagulantes/farmacocinética , Hidrocarburo de Aril Hidroxilasas/genética , Hidrocarburo de Aril Hidroxilasas/metabolismo , Warfarina/administración & dosificación , Warfarina/farmacocinética , Adulto , Alelos , Citocromo P-450 CYP2C9 , Femenino , Frecuencia de los Genes , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Pakistán , Polimorfismo Genético , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
9.
J Diet Suppl ; 17(1): 13-26, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-30299180

RESUMEN

The present study aimed to evaluate the therapeutic and prophylactic potential of Coriandrum sativum extract in isoproterenol-induced heart failure (HF) in Wistar rats. Two weeks after the isoproterenol administration, rats developed severe impairment in left ventricular functions, reduced baroreflex sensitivity, and significant alteration in hemodynamic parameters and lipid profile. HF rats also exhibited enhanced lipid peroxidation and increased expression of endothelin receptors (ETA and ETB). Therapeutic and prophylactic treatment with C. sativum extract significantly (p < .05) improved the left ventricular functions and hemodynamic parameters and increased baroreflex sensitivity. It also inhibited lipid peroxidation, improved lipid profile, and downregulated the expression of endothelin receptors. Simvastatin treatment showed a similar cardioprotective effect. Our results suggest that C. sativum extract provides significant protection from heart failure possibly due to its ability to improve left ventricular functions and baroreflex sensitivity, attenuate lipid peroxidation, and modulate the expression of endothelin receptors.


Asunto(s)
Antioxidantes/farmacología , Coriandrum , Insuficiencia Cardíaca/prevención & control , Estrés Oxidativo/efectos de los fármacos , Fitoterapia , Extractos Vegetales/farmacología , Receptores de Endotelina/metabolismo , Animales , Antioxidantes/uso terapéutico , Barorreflejo/efectos de los fármacos , Femenino , Insuficiencia Cardíaca/metabolismo , Hemodinámica , Isoproterenol , Peroxidación de Lípido/efectos de los fármacos , Lípidos/sangre , Masculino , Extractos Vegetales/uso terapéutico , Sustancias Protectoras/farmacología , Sustancias Protectoras/uso terapéutico , Ratas Wistar , Semillas , Función Ventricular Izquierda/efectos de los fármacos
10.
J Environ Pathol Toxicol Oncol ; 37(4): 273-289, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30806235

RESUMEN

The protective efficacy of methanolic bark extract of Acacia catechu Willd. (MEBA) against 1,2-dimethylhydrazine (DMH)-induced colon toxicity was investigated. Acacia catechu is considered one of the most potent medicines for various diseases in Ayurveda, a traditional system of Indian medicine. It is a widely used herb that contains a variety of bioactive components such as phenolic acids, alkaloids, and flavonoids among others. In the present study, MEBA was used as a pretreatment orally at two doses (250 and 500 mg/kg body weight [b.w.] once daily for 7 days), and DMH was administered (at a dose of 40 mg/kg b.w.) subcutaneously on day 7 in Wistar rats. The protective potential of MEBA was assessed in terms of the activity of antioxidant enzymes, lipid peroxidation, and expression of inflammatory markers (iNOS, COX-2, NF-κB, IL-6). Pretreatment with MEBA significantly abrogated oxidative damage by diminishing tissue lipid peroxidation, increasing enzymatic activities of various antioxidant enzymes (catalase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase, reduced glutathione), and diminishing the induced expression of inflammatory markers in the colon tissue of Wistar rats. Furthermore, histopathological findings revealed that pretreatment with (MEBA) reduced intense filtration of inflammatory cells and significantly restored the architecture of colonic tissue. The results of this study indicate that MEBA significantly suppresses DMH-induced toxicity by ameliorating oxidative stress and inflammation and by restoring the architecture of colon tissue.


Asunto(s)
1,2-Dimetilhidrazina/toxicidad , Acacia , Carcinógenos/toxicidad , Colon/efectos de los fármacos , Corteza de la Planta , Extractos Vegetales/farmacología , Sustancias Protectoras/farmacología , Animales , Biomarcadores/metabolismo , Colon/metabolismo , Colon/patología , Esquema de Medicación , Femenino , Inflamación/inducido químicamente , Inflamación/metabolismo , Inflamación/patología , Inflamación/prevención & control , Metanol , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/fisiología , Fitoterapia/métodos , Plantas Medicinales , Distribución Aleatoria , Ratas , Ratas Wistar
11.
Pharmacol Rep ; 69(5): 1007-1013, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28939345

RESUMEN

BACKGROUND: Cisplatin (CP) is a potent chemotherapeutic agent commonly used for the treatment of various malignancies. It has varied undesirable effects such as nephrotoxicity, intestinal toxicity which limit its wide and extensive clinical usage. 18ß-Glycyrrhetinic acid (GA) is a pentacyclic triterpenoid derivative, obtained from the herb liquorice having pharmacological properties such as anti-inflammatory, hepatoprotective and antioxidant. The present study was designed to investigate in vivo efficacy of GA against CP induced small intestinal toxicity. METHODS: Rats were subjected to prophylactic oral treatment of GA (50 and 100mg/kg body weight) for 21days against intestinal toxicity induced by single intra peritoneal injection of CP (10mg/kg body weight) on day 18th and sacrificed on 21st day. RESULTS: The plausible mechanism of CP induced small intestinal toxicity is via deficit in anti-oxidant armory, induction of oxidative stress; TNF-α, NFkB, activation of apoptotic pathway proteins by up regulation of caspases. However prophylactic treatment of GA diminished oxidative stress markers, TNF-α, NFkB expression and enhanced anti-oxidant status, down regulated apoptosis, recovered histopatholgical alterations in small intestine. CONCLUSION: Therefore, results of the present finding provide strong evidence that GA may be a useful modulator in alleviating CP induced intestinal toxicity.


Asunto(s)
Caspasas/metabolismo , Cisplatino/toxicidad , Ácido Glicirretínico/análogos & derivados , Enfermedades Intestinales/inducido químicamente , FN-kappa B/metabolismo , Animales , Biomarcadores , Regulación de la Expresión Génica/efectos de los fármacos , Glutatión/metabolismo , Ácido Glicirretínico/farmacología , Masculino , Estrés Oxidativo , Distribución Aleatoria , Ratas , Ratas Wistar
12.
J Hematol Oncol ; 5: 57, 2012 Sep 18.
Artículo en Inglés | MEDLINE | ID: mdl-22989009

RESUMEN

BACKGROUND: Lymphomas frequently retain wild-type (wt) p53 function but overexpress HDM2, thereby compromising p53 activity. Therefore, lymphoma is a suitable model for studying the therapeutic value of disrupting the HDM2-p53 interaction by small-molecule inhibitors (SMIs). HDM2 have been developed and are under various stages of preclinical and clinical investigation. Previously, we examined the anti-lymphoma activity of MI-319, the laboratory grade of a new class of HDM2 SMI, the spiro-oxindole, in follicular lymphoma. Since then, MI-219, the clinical grade has become readily available. This study further examines the preclinical effects and mechanisms of MI-219 in a panel of human lymphoma cell lines as well as a cohort of patient-derived B-lymphocytes for its potential clinical use. RESULTS: Preclinical assessment of MI-219 was evaluated by means of an in vitro and ex vivo approach and compared to Nutlin-3, the gold standard. Characterization of p53 activity and stability were assessed by quantitative PCR, Western blot, and immunoprecipitation. Biological outcome was measured using Trypan blue exclusion assay, Annexin V/PI, PARP and caspase-3 cleavage. Surprisingly, the overall biological effects of Nutlin-3 were more delayed (48 h) while MI-219 triggered an earlier response (12-24 h), predominantly in the form of apoptotic cell death. Using a cell free autoubiquitination assay, neither agent interfered with HDM2 E3 ligase function. MI-219 was more effective in upregulating wt-p53 stabilization compared to Nutlin-3. MI-219, but not Nutlin-3, enhanced the autoubiquitination and degradation of HDM2. CONCLUSIONS: Our data reveals unexpected differences between MI-219 and the well-studied Nutlin-3 in lymphoma cell lines and patient samples. We suggest a novel mechanism for MI-219 that alters the functional activity of HDM2 through enhanced autoubiquitination and degradation. Additionally, this mechanism appears to correspond to biological outcome. Our results provide evidence that different classes of HDM2 SMIs elicit molecular events that extend beyond HDM2-p53 dissociation which may be of biological and potentially therapeutic importance.


Asunto(s)
Imidazoles/farmacología , Indoles/farmacología , Linfoma de Células B/tratamiento farmacológico , Linfoma de Células B/metabolismo , Piperazinas/farmacología , Proteínas Proto-Oncogénicas c-mdm2/antagonistas & inhibidores , Compuestos de Espiro/farmacología , Proteína p53 Supresora de Tumor/metabolismo , Anciano , Anciano de 80 o más Años , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Femenino , Humanos , Linfoma de Células B/patología , Masculino , Persona de Mediana Edad , Proteínas Proto-Oncogénicas c-mdm2/metabolismo , Ubiquitinación/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA